Published in J Rheumatol on December 01, 2004
An exploration of the inter- and intra-rater reliability of the Bath Ankylosing Spondylitis Metrology Index. Clin Rheumatol (2012) 0.87
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. Rheumatology (Oxford) (2014) 0.82
Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different? Ann Rheum Dis (2006) 0.81
Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (Hoboken) (2013) 0.77
Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy. J Korean Med Sci (2008) 0.77
Inter-rater reliability of clinical mobility measures in ankylosing spondylitis. BMC Musculoskelet Disord (2016) 0.75
The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) (2010) 12.31
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol (2011) 4.72
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol (2007) 3.41
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol (2002) 2.71
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52
A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol (2003) 2.30
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther (2009) 2.05
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum (2002) 1.97
Steroid injection for osteoarthritis of the hip: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2007) 1.83
An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol (2005) 1.77
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum (2008) 1.73
Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum (2005) 1.71
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol (2010) 1.64
Use of a case manager to improve osteoporosis treatment after hip fracture: results of a randomized controlled trial. Arch Intern Med (2007) 1.63
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2007) 1.56
Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol (2009) 1.54
Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol (2005) 1.52
High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease. Arthritis Rheum (2004) 1.51
Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum (2007) 1.49
Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol (2006) 1.49
Development and validation of a magnetic resonance imaging reference criterion for defining a positive sacroiliac joint magnetic resonance imaging finding in spondyloarthritis. Arthritis Care Res (Hoboken) (2013) 1.47
The role of anti-cyclic citrullinated peptide antibodies in predicting progression of palindromic rheumatism to rheumatoid arthritis. J Rheumatol (2006) 1.44
The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol (2007) 1.44
Evidence in support of the validity of the TNF brake hypothesis. Ann Rheum Dis (2013) 1.41
Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. J Rheumatol (2011) 1.40
Alberta rodeo athletes do not develop the chronic whiplash syndrome. J Rheumatol (2006) 1.39
Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum (2008) 1.38
Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ (2008) 1.35
Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol (2007) 1.35
Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum (2011) 1.32
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol (2011) 1.31
ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis (2010) 1.30
The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum (2010) 1.27
Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis (2012) 1.26
Regional musculoskeletal conditions: neck pain. Best Pract Res Clin Rheumatol (2003) 1.22
Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities. Arthritis Res Ther (2011) 1.22
A population-based survey of back pain beliefs in Canada. Spine (Phila Pa 1976) (2006) 1.19
Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum (2005) 1.17
Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum (2011) 1.14
Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol (2006) 1.14
Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol (2002) 1.12
Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum (2004) 1.12
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol (2007) 1.11
Appropriateness of healthcare interventions: concepts and scoping of the published literature. Int J Technol Assess Health Care (2008) 1.11
The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. J Rheumatol (2004) 1.10
Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol (2007) 1.08
Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med (2009) 1.08
Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol (2009) 1.06
International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. J Rheumatol (2007) 1.04
Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther (2012) 1.04
Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol (2011) 1.04
Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis Rheum (2004) 1.03
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat. Arthritis Rheum (2010) 1.03
Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol (2015) 1.02
Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis Rheum (2011) 1.00
Systematic assessment of inflammation by magnetic resonance imaging in the posterior elements of the spine in ankylosing spondylitis. Arthritis Care Res (Hoboken) (2010) 0.99
A questionnaire using the modified 2010 American College of Rheumatology criteria for fibromyalgia: specificity and sensitivity in clinical practice. J Rheumatol (2013) 0.99
Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population. Arthritis Rheum (2006) 0.98
Can erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study. Arthritis Res Ther (2012) 0.97
Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol (2007) 0.96
Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol (2006) 0.95
High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheum (2003) 0.95
Advantages and limitations of utility assessment methods in rheumatoid arthritis. J Rheumatol (2007) 0.94
Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent-onset inflammatory back pain. Arthritis Rheum (2009) 0.94
Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum (2009) 0.93
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol (2011) 0.92
Educational intervention to reduce falls and fear of falling in patients after fragility fracture: results of a controlled pilot study. Prev Med (2006) 0.92
Diagnostic utility of candidate definitions for demonstrating axial spondyloarthritis on magnetic resonance imaging of the spine. Arthritis Rheumatol (2015) 0.92
Relative urgency for referral from primary care to rheumatologists: the Priority Referral Score. Arthritis Care Res (Hoboken) (2011) 0.91
Simple educational intervention to improve the recovery from acute whiplash: results of a randomized, controlled trial. Acad Emerg Med (2005) 0.90
Magnetic resonance imaging for spondyloarthritis--avoiding the minefield. J Rheumatol (2007) 0.90
A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. J Am Acad Dermatol (2006) 0.90
Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis. Arthritis Care Res (Hoboken) (2010) 0.90
Does height influence the assessment of spinal and hip mobility measures used in ankylosing spondylitis? J Rheumatol (2006) 0.90
Latitude gradient influences the age of onset in rheumatoid arthritis patients. Clin Rheumatol (2007) 0.90
Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum (2013) 0.89
HLA and cytokine gene polymorphisms in relation to occurrence of palindromic rheumatism and its progression to rheumatoid arthritis. J Rheumatol (2002) 0.89
14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther (2014) 0.89
Priority-setting for children's mental health: clinical usefulness and validity of the priority criteria score. J Can Acad Child Adolesc Psychiatry (2007) 0.89
Interventions to increase osteoporosis treatment in patients with 'incidentally' detected vertebral fractures. Am J Med (2012) 0.89
Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI. Ann Rheum Dis (2009) 0.89